India, Sept. 25 -- Rapport Therapeutics Inc. (RAPP), a clinical-stage biotechnology company, has been steadily advancing its precision neuroscience pipeline, positioning itself as an increasingly notable contender in the evolving landscape of epilepsy treatment.
The company's lead investigational drug, RAP-219, is being developed for epilepsy, including focal-onset seizures (FOS) and primary generalized tonic-clonic seizures, as well as bipolar mania. Rapport is also advancing additional discovery and preclinical programs leveraging its platform in chronic pain, migraine, and hearing and vestibular disorders.
When Did We Highlight RAPP?
We featured Rapport Therapeutics on our site on May 21, 2025, when the stock was at $10.26. Our report...